
Edward Jae Hoon Kim MD PhD
Gastrointestinal Cancer
Professor of Medicine Ken and Cindy Blumenthal Endowed Professor for Pancreatic Cancer Research Medical Director - Office of Clinical Research Medical Director - Cancer Care Network Associate Director - MD/PhD Program UC Davis Comprehensive Cancer Center
Join to View Full Profile
4501 X St2nd FloorSacramento, CA 95817
Phone+1 916-734-5959
Fax+1 916-703-5265
Dr. Kim is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Edward Kim is a medical oncology physician scientist at the UC Davis Comprehensive Cancer Center where he specializes in gastrointestinal malignancies. He graduated from Harvard University and received his MD/PhD from Stony Brook University School of Medicine and has been in practice 12 years.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2007 - 2011
University of MichiganResidency, Internal Medicine, 2005 - 2007
Stony Brook University Health Sciences Center School of MedicineClass of 2005
Harvard UniversityAB, Chemistry, Magna cum laude, 1993 - 1997
Certifications & Licensure
CA State Medical License 2012 - 2028
MI State Medical License 2005 - 2015
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
- RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) Start of enrollment: 2016 Aug 30
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer Start of enrollment: 2018 Oct 16
Publications & Presentations
PubMed
- NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer.Margaret C Wheless, Shannon Stockton, Heloisa P Soares, Farshid Dayyani, Anwaar Saeed
The Oncologist. 2025-12-01 - Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).Liza C Villaruz, Jingxiao Jin, Hong Wang, James J Lee, Jason J Luke
Cancer. 2025-11-01 - 6 citationsNCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha
British Journal of Cancer. 2024-02-01
Press Mentions
$3 Million National Grant to Fund Pancreatic Cancer StudyFebruary 7th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:















